Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

93 trials with published results (29%)

Research Maturity

238 completed trials (73% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.1%

20 terminated out of 326 trials

Success Rate

92.2%

+5.7% vs benchmark

Late-Stage Pipeline

18%

59 trials in Phase 3/4

Results Transparency

39%

93 of 238 completed with results

Key Signals

93 with results92% success20 terminated

Data Visualizations

Phase Distribution

253Total
Not Applicable (112)
Early P 1 (3)
P 1 (44)
P 2 (35)
P 3 (25)
P 4 (34)

Trial Status

Completed238
Recruiting23
Terminated20
Unknown19
Active Not Recruiting11
Withdrawn7

Trial Success Rate

92.2%

Benchmark: 86.5%

Based on 238 completed trials

Clinical Trials (326)

Showing 20 of 20 trials
NCT06117163Not ApplicableRecruitingPrimary

Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study

NCT04958122Phase 3Recruiting

Cefixime Clinical Trial

NCT04865341Not ApplicableCompletedPrimary

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

NCT06132672Not ApplicableNot Yet RecruitingPrimary

Medical Mistrust Among Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex With Men (HLMSM)

NCT05404750RecruitingPrimary

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

NCT06519994Phase 2CompletedPrimary

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

NCT06819176Phase 1RecruitingPrimary

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT07530198Phase 1RecruitingPrimary

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

NCT05537935Phase 4RecruitingPrimary

Low Dose Naltrexone for Pain in Patients With HIV

NCT01420523Phase 2TerminatedPrimary

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

NCT05245292Phase 1CompletedPrimary

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

NCT05452564Phase 2RecruitingPrimary

Baricitinib for Reduction of HIV - CNS

NCT06253533Phase 1CompletedPrimary

ICVAX as a HIV Therapeutic DNA Vaccine

NCT06035445Not ApplicableActive Not RecruitingPrimary

Support for Adolescents Living With HIV in South Africa

NCT05991622Phase 2WithdrawnPrimary

Combined Injectable Treatment for HIV and OUD

NCT05413811Not ApplicableCompleted

Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV

NCT03904186Not ApplicableCompletedPrimary

Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV

NCT05495906Phase 4Recruiting

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

NCT03300830RecruitingPrimary

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

NCT06408142RecruitingPrimary

Universal Test and Connect for HIV Service Delivery in South Africa

Scroll to load more

Research Network

Activity Timeline